Boehringer Ingelheim

For Healthcare Professionals

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Area

Section Overview

Cardiovascular

Metabolic

Inflammation

Respiratory
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See all products

Products

See all products
Resources
Contact
Logout

Boehringer Ingelheim

Expert's Video
Prescribing Information
Jardiance HF

banner-heartfailure-desktop

EXPERT'S VIDEO

Empagliflozin (JARDIANCE) in low eGFR HFrEF patients

0:54

Empagliflozin (JARDIANCE) in low eGFR HFrEF patients

Watch now Opens in new tab

How Empagliflozin (JARDIANCE) 10 mg provide Cardio-Renal benefits in HFrEF

6:00

How Empagliflozin (JARDIANCE) 10 mg provide Cardio-Renal benefits in HFrEF

Watch now Opens in new tab

Consistent CV benefits in HFrEF

3:28

Consistent CV benefits in HFrEF

Watch now Opens in new tab

Empagliflozin (JARDIANCE) is simple and easy to use

1:38

Empagliflozin (JARDIANCE) is simple and easy to use

Watch now Opens in new tab

Empagliflozin (JARDIANCE)'s Consistent CV and Renal Benefits in HFrEF

42:25

Empagliflozin (JARDIANCE)'s Consistent CV and Renal Benefits in HFrEF

Watch now Opens in new tab

Jardiance 10mg is Safe in Heart failure

1:32

Jardiance 10mg is Safe in Heart failure

Watch now Opens in new tab

Home
Experts Video

Sitemap

Therapeutic Area

Resources
- Videos
- Clinical studies

BI logo

Privacy
Terms of use
Sitemap
Contact

Copyright © 2025 Boehringer Ingelheim (Philippines), Inc. All rights reserved. Use of this Site is subject to the Terms of Use and Privacy Statement. Prepared June 2025